Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.
Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedThe website has updated the intervention details and results reporting dates, including the addition of new results and study documents from Ryan Lynch, while removing outdated information and previous revision details.SummaryDifference7%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe website has updated to version v2.13.3, adding 'Results Submitted' while removing 'No Results Posted' from the previous version v2.13.2.SummaryDifference0.2%
- Check39 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference3%
- Check53 days agoChange DetectedSeveral links to medical resources and drug information have been removed, indicating a significant reduction in available references for lymphoma and related treatments.SummaryDifference5%
- Check68 days agoChange DetectedNew resources related to lymphoma and treatment options have been added, including links to MedlinePlus and DailyMed for various drugs, while the previous version has been updated from v2.12.1 to v2.12.2.SummaryDifference5%
- Check75 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.